Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 2c

March 18, 2019 4:23 PM EDT

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

2018 was a transformational year for Catalyst with the approval of Firdapse® (amifampridine phosphate) tablets, the first and only evidence-based, FDA approved treatment for patients with Lambert-Eaton myasthenic syndrome... More